CompletedInterventionalPhase 4Updated Jan 28, 2014
A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) | NCT01632423 | Trialant
CompletedObservationalUpdated Sep 21, 2012
A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
ClinicalTrials.gov ID
NCT01632423
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Observational
Enrollment
10,337Actual
Last Update Posted
Sep 21, 2012Estimated
Start Date
Feb 2010
Primary Completion Date
Nov 2010Actual
Completion Date
Nov 2010Actual
Brief Summary
This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
Glaucoma, Open-Angle
Ocular Hypertension
bimatoprost 0.01%
Ages Eligible for Study
Child (0-17)Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosed with primary open angle glaucoma or ocular hypertension